市场调查报告书
商品编码
1470458
生物模拟市场:按产品、交付模式、最终用户、应用划分 - 2024-2030 年全球预测Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年生物模拟市场规模为38.1亿美元,预计2024年将达44亿美元,2030年将达98.7亿美元,复合年增长率为14.55%。
生物模拟结合了数学、生物学和电脑程式设计来创建模拟来检验假设、预测结果并探索生物技术的新可能性。生物模拟透过模拟基因表现、新陈代谢和细胞生长等生物现象,帮助研究人员更好地了解生命的复杂性并开发医疗保健新产品。随着新药和药品开发的不断进步,以及政府专注于将数位化位技术整合到製药和生物製药领域,对生物模拟系统的需求不断增加。然而,开发模拟软体的高成本阻碍了市场的成长。由于电脑辅助设计(CAD)和虚拟实境(VR)技术的日益融合,以及人工智慧(AI)和机器学习(ML)在新模拟软体开发中的进步,生物模拟市场预计将扩大马苏。
主要市场统计 | |
---|---|
基准年[2023] | 38.1亿美元 |
预测年份 [2024] | 44亿美元 |
预测年份 [2030] | 98.7亿美元 |
复合年增长率(%) | 14.55% |
生物模拟软体为模型建构、模拟、分析和视觉化提供平台,其使用正在不断增加。
合约服务由专业公司和研究组织提供,为其客户提供生物模拟专业知识,支援模型开发、模拟研究、资料分析和解释。内部服务是在组织或研究机构内执行的生物模拟服务。分子建模和模拟软体专注于对蛋白质、核酸和小分子等分子的行为进行模拟和建模。它用于研究分子之间的相互作用和结构变化,并预测结合亲和性等特性。 PBPK建模和模拟软体旨在模拟药物和化学物质的生物分布、吸收、代谢和排泄。 PK/PD、建模和模拟软体影响药物的药物动力学和动态特性,帮助预测药物浓度和暴露-反应关係,并优化给药方案。毒性预测软体专注于预测化合物的潜在毒性。计算模型用于评估接触特定化学物质和药物的安全性和潜在风险。临床试验设计软体支援临床试验设计和最佳化,模拟各种临床试验场景,评估统计功效,优化样本大小,以提高临床试验的效率和有效性。
交付模型:生物模拟倾向于支援为使用者提供完全控制的所有权模型。
生物模拟的所有权模型允许使用者购买软体和服务,并完全控制软体及其使用方式。在生物模拟所有权模型中,使用者购买软体的永久许可证,并被授予无限期使用该软体的权利。在订阅模式中,使用者支付经常性费用才能存取和使用软体和服务。在此模型中,使用者通常不拥有该软体,但可以持续存取最新版本和更新。
最终用户:製药和生物技术公司越来越多地采用生物模拟
委外研发机构(CRO) 经常利用生物模拟来支援客户的药物发现和研发流程,包括使用生物模拟技术进行分子建模、PK/PD 建模、毒性预测等。製药和生物技术公司在其药物开发平臺中广泛采用生物模拟。包括美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 在内的监管机构在核准药品上市之前评估药品的安全性和有效性方面发挥着重要作用。监管机构使用生物模拟来评估药物的风险效益状况、优化研究设计并在医药品认证过程中做出明智的决定。学术机构和政府机构等研究组织使用生物模拟来提高科学知识并进行高级研究。研究人员使用生物模拟工具和技术来建模和模拟复杂的生物系统,探索假设,并深入了解基本的生物过程。
将生物模拟的应用扩展到应用药物开发
生物模拟提供有关药物的药物动力学 (PK) 和动态(PD) 特性的见解和预测,以优化给药方案、预测目标组织中的药物浓度以及候选药物的潜在功效和安全性,它在药物开发中发挥重要作用。 PBPK 和 PK/PD 建模等生物模拟技术可支援药物开发中的明智决策。生物模拟支持临床试验的设计和最佳化,并能够预测和评估药物和化合物的吸收、分布、代谢、排泄和毒性特性。生物模拟可以在药物开发过程的早期识别潜在的 ADME/Tox 问题,从而减少广泛的动物测试的需要并提供对潜在风险的洞察。 PK/PD建模和模拟可以预测药物暴露和反应性之间的关係。生物模拟透过采用分子建模和模拟技术来支持先导化合物的识别和最佳化。帮助筛检和评估潜在的候选药物,预测与目标分子的结合亲和性,并优化化学结构以提高效力和选择性。生物模拟技术可以帮助识别和检验潜在的药物标靶。生物模拟透过建模和模拟药物分子与目标蛋白之间的相互作用,有助于评估靶向特定蛋白的可行性和潜在有效性。
区域洞察
美洲地区是生物模拟市场高度发展的地区。这是由于美国现有主要参与者的存在以及他们对推进模拟软体的持续努力。 FDA(美国食品药物管理局)、EMA(欧洲药品管理局)和加拿大卫生署等监管机构的成立,确保药物开发和临床试验的安全性和效率,为亚太地区的市场成长做出贡献。 。就欧洲、中东和非洲地区而言,英国、德国和法国对药物开发和临床试验的投资增加正在推动模拟软体和服务的采用。亚太地区慢性病的增加预计将促使各国政府和监管机构加强对药物开发的资助力度,为生物模拟市场的开拓提供平台。针对药物研发 (R&D) 活动的各种倡议的存在,例如澳洲药物发现计划和医学研究商业化计划,正在扩大生物模拟在亚太地区的使用。
FPNV定位矩阵
FPNV定位矩阵对于评估生物模拟市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对生物模拟市场中供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.生物模拟市场的市场规模与预测是多少?
2.在生物模拟市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.生物模拟市场的技术趋势和法规结构是什么?
4.生物模拟市场主要厂商的市场占有率为何?
5. 进入生物模拟市场的合适型态和策略手段是什么?
[197 Pages Report] The Biosimulation Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.40 billion in 2024, at a CAGR 14.55% to reach USD 9.87 billion by 2030.
Biosimulation combines mathematics, biology, and computer programming to create simulations to test hypotheses, predict outcomes, and explore new possibilities in biotechnology. By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.81 billion |
Estimated Year [2024] | USD 4.40 billion |
Forecast Year [2030] | USD 9.87 billion |
CAGR (%) | 14.55% |
Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
Contract services are provided by specialized companies and research organizations that offer biosimulation expertise to clients, which assist with model development, simulation studies, data analysis, and interpretation. In-house services are biosimulation services conducted within an organization and research institution. Molecular modeling & simulation software focuses on simulating and modeling the behavior of molecules, such as proteins, nucleic acids, and small molecules. It is used to study molecular interactions and conformational changes and predict properties such as binding affinity. PBPK modeling & simulation software is designed to simulate the distribution, absorption, metabolism, and excretion of drugs and chemicals in the body. PK/PD, modeling & simulation software, affects drugs' pharmacokinetic and pharmacodynamic properties, helps predict drug concentrations and exposure-response relationships, and optimizes dosing regimens. Toxicity prediction software focuses on predicting the potential toxicity of chemical compounds. It uses computational models to assess the safety and potential risks of exposure to specific chemicals or drugs. Trial design software helps in the design and optimization of clinical trials and also simulates different trial scenarios, evaluates statistical power, and optimizes sample sizes to improve the efficiency and validity of clinical studies.
Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
In the biosimulation ownership model, users purchase the software and service outright, giving them full control over the software and its usage. In the biosimulation ownership model, users purchase a perpetual license for the software, granting them the right to use it indefinitely. Subscription models involve users paying a recurring fee to access and use the software or services. With this model, users usually do not own the software but have ongoing access to the latest versions and updates.
End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
Contract research organizations (CROs) often utilize biosimulation to support their clients' drug discovery and development processes and offer services such as molecular modeling, PK/PD modeling, toxicity prediction, and trial design using biosimulation techniques. Pharmaceutical & biotechnology companies extensively employ biosimulation throughout the drug development pipeline. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in evaluating drug safety and effectiveness before being approved for market release. Regulatory authorities use biosimulation to assess the risk-benefit profile of drugs, optimize study designs, and make informed decisions during the drug approval process. Research institutes, including academic institutions and government organizations, employ biosimulation to advance scientific knowledge and conduct advanced research. Researchers utilize biosimulation tools and techniques to model and simulate complex biological systems, explore hypotheses, and gain insights into fundamental biological processes.
Application: Increasing application of biosimulation for drug development
Biosimulation plays a vital role in drug development by providing insights and predictions related to drug pharmacokinetic (PK) and pharmacodynamic (PD) properties, assisting in optimizing dosing regimens, predicting drug concentrations in target tissues, and assessing drug candidates' potential efficacy and safety. Biosimulation techniques, such as PBPK and PK/PD modeling, aid in making informed decisions during drug development. Biosimulation supports the design and optimization of clinical trials and enables the prediction and evaluation of drugs and chemical compounds' absorption, distribution, metabolism, excretion, and toxicity properties. Biosimulation helps identify potential ADME/Tox issues early in the drug development process, reducing the need for extensive animal testing and providing insights into potential risks. PK/PD modeling and simulation assist in predicting the relationship between drug exposure and response. Biosimulation supports lead identification & optimization by employing molecular modeling and simulation techniques. It aids in screening and evaluating potential drug candidates, predicting their binding affinity to target molecules, and optimizing their chemical structures for improved potency and selectivity. Biosimulation techniques aid in the identification and validation of potential drug targets. By modeling and simulating the interactions between drug molecules and target proteins, biosimulation helps evaluate the feasibility and potential effectiveness of targeting specific proteins.
Regional Insights
The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Biosimulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Biosimulation Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimulation Market?
3. What are the technology trends and regulatory frameworks in the Biosimulation Market?
4. What is the market share of the leading vendors in the Biosimulation Market?
5. Which modes and strategic moves are suitable for entering the Biosimulation Market?